Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:37:35.527Z.
Calculation as of: 2026-10-06T21:37:35.527Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a8aae8e93f82a899e51ff603ce0499f2ee8a4244ac8b174beef8711f00adb15
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Spectral AI, Inc.
Market Cap
$52.83M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Spectral AI, Inc. (MDAI) | $52.83M | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | N/A |
| ImageneBio Inc (IMA)vs › | $51.88M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $54.14M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A |
| Aldeyra The (ALDX)vs › | $55.25M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
